-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $15

Benzinga·11/13/2025 18:22:10
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $13 to $15.